A Comparison of the Clinical Effectiveness Between Low-Dose Strong Opioids and Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Mild Cancer Pain: A Randomized Trial
Mei-Zuo Liu,Jian Ma,Jun-Dong Li,Jing Sun,Hua Zhou,Shuo Guan,Ying Han,Xia Zhang,Ji-Lai Bian
DOI: https://doi.org/10.2147/JPR.S322893
IF: 2.8319
2021-11-02
Journal of Pain Research
Abstract:Mei-Zuo Liu, 1 Jian Ma, 2 Jun-Dong Li, 1 Jing Sun, 1 Hua Zhou, 1 Shuo Guan, 1 Ying Han, 1 Xia Zhang, 3 Ji-Lai Bian 1 1 Department of Oncology, The Fifth People's Hospital of Dalian, Dalian, 116000, People's Republic of China; 2 Intensive Care Unit, The Fifth People's Hospital of Dalian, Dalian, 116000, People's Republic of China; 3 Medical Examination Center, The Fifth People's Hospital of Dalian, Dalian, 116000, People's Republic of China Correspondence: Ji-Lai Bian Department of Oncology, The Fifth People's Hospital of Dalian, No. 890 of Huanghe Street, Shahekou District, Dalian, 116000, People's Republic of China Tel +86 13941195981 Fax +86 13941195981 Email Objective: The present study aims to explore the effectiveness and safety of low-dose strong opioids compared with non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of mild cancer pain. Methods: From September 2016 to September 2018, 66 patients with a malignant tumor and mild cancer pain admitted to the Department of Oncology of Dalian Fifth People's Hospital were divided into the group A (treated with ibuprofen sustained-release tablets for pain relief) and the group B (treated with oxycodone hydrochloride sustained-release tablets for pain relief). After 7 days of treatment, the pain relief (Numeric Rating Scale [NRS]), physical strength, quality of life scores (Zubrod/ECOG/WHO [ZPS]), the Edmonton Symptom Assessment System [ESAS], and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core15-Palliative [EORTC QLQ-C15-PAL] scores), and the occurrence of adverse reactions between the two groups were compared. The occurrence of adverse reactions in the mid-term (after one month and three months of treatment) between the two groups were also compared. Results: Both groups had over 90% analgesic efficiency, but complete pain relief was more likely to be obtained in the group B (41.18%). The total analgesic efficiency in the group B was higher (100%) than in the group A (98.9%), and the difference was statistically significant (P < 0.05). The differences in the physical strength and quality of life scores in the two groups before and after treatment were statistically significant (P < 0.05). The differences in the ZPS scores between the two groups were statistically significant (P 0.05). Conclusion: The application of low-dose oxycodone hydrochloride sustained-release tablets as the initial medication for patients with mild cancer pain was safe and effective, and the adverse reactions were easy to manage. Keywords: oxycodone hydrochloride sustained-release tablet, non-steroidal anti-inflammatory drugs, mild cancer pain, clinical effect At least 1/3 of patients newly diagnosed with a malignant tumor and 70–90% of patients with advanced tumors have pain. 1 Pain can directly affect the quality of life in patients with malignant tumors. Patients with cancer pain often have limited activities, sadness, anxiety, and clinical depression, along with suicidal tendencies. Their quality of life is significantly lower than in patients with cancer but lacking pain. In 1982, the World Health Organization (WHO) established a three-step cancer pain treatment program, with the goal of "making cancer patients pain-free by the year 2000". In 2012, the European Society for Medical Oncology (ESMO) recommended low-dose strong opioids or a combination of non-opioid analgesics as an alternative to weak opioids in mild to moderate cancer pain management. 2 However, in the current clinical practice for cancer pain, most patients with mild pain have difficulty receiving early treatment with strong opioids due to the fact that some clinicians may not thoroughly understand the WHO pain relief principles or adopt the latest treatment options. There is a fear of drug addiction among patients, families, or even doctors due to insufficient knowledge about the drugs, the relatively strict control, and the difficulty in prescribing. This has become the weakest area of palliative care in China. 3,4 At present, for mild cancer pain, non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are often used clinically as first-step drugs. The National Comprehensive Cancer Network (NCCN) guidelines for adult cancer pain 5 mention caution with the application of NSAIDs, especially in patients on long-term administration, and many oncology patients are at high risk for renal disease, gastrointestinal (GI) tract risk (upper GI surgery, radiation th -Abstract Truncated-
clinical neurology